Sexually Transmitted Diseases
16 treatments and conditions followed through the public trial records. Not medical advice. How a status is set
Lists the pairs whose condition is this category or one beneath it. A category is not a diagnosis and not advice.
Broader: Communicable Diseases, Infections
Narrower: Gonorrhea 6, Herpes Genitalis 3, Papillomavirus Infections 6
Treatments and conditions
| Treatment and condition | Where it stands | Trials |
|---|---|---|
| 4CMenB vaccine for gonorrhea | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| 9vHPV Vaccine for papillomavirus infections | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Circulating Tumor DNA test (ctDNA test) + Dose de-escalation to contralateral neck. + Dose de-escalation to gross disease + Dose de-escalation to gross disease to contralateral neck for papillomavirus infections | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| EGCG and Quinine Sulfate Vaginal Suppository for papillomavirus infections | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Gepotidacin for gonorrhea | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Meningococcal Group B Vaccine for gonorrhea | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| pBI-11 (1 dose) + Placebo (2 doses) for papillomavirus infections | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| pBI-11 (3 doses) for papillomavirus infections | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo for herpes genitalis | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Standardized kudzu for sexually transmitted diseases | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Temocillin (NEGABAN®) 2 g intramuscular single dose with lidocaine (3ml) for gonorrhea | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Temocillin (NEGABAN®) 2 g intravenous with lidocaine (3ml) for gonorrhea | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tetanus-Diphtheria booster for papillomavirus infections | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| UB-621 high-dose for herpes genitalis | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| UB-621 low-dose for herpes genitalis | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Zoliflodacin for gonorrhea | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
Categories are from Medical Subject Headings (MeSH), U.S. National Library of Medicine, courtesy of the U.S. National Library of Medicine: MeSH. They may not reflect the most current data available from NLM. NLM does not endorse this site.